Ascletis Pharma Stock Analysis

Ascletis Pink Sheet Analysis Notes

About 67.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ascletis Pharma recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.The quote for Ascletis Pharma is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Ascletis Pharma please contact the company at 86 571 8538 9730 or go to https://www.ascletis.com.

Ascletis Pharma Investment Alerts

Ascletis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 672.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascletis Pharma's market, we take the total number of its shares issued and multiply it by Ascletis Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Ascletis Profitablity

The company has Profit Margin (PM) of (2.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.11.

Technical Drivers

As of the 2nd of December, Ascletis Pharma shows the mean deviation of 1.26, and Risk Adjusted Performance of 0.0789. Ascletis Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Ascletis Pharma coefficient of variation, as well as the relationship between the total risk alpha and skewness to decide if Ascletis Pharma is priced correctly, providing market reflects its regular price of 0.18 per share. As Ascletis Pharma appears to be a penny stock we also recommend to validate its information ratio numbers.

Ascletis Pharma Price Movement Analysis

Ascletis Pharma Predictive Daily Indicators

Ascletis Pharma Forecast Models

Ascletis Pharma's time-series forecasting models are one of many Ascletis Pharma's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ascletis Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Ascletis Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ascletis shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Ascletis Pharma. By using and applying Ascletis Pink Sheet analysis, traders can create a robust methodology for identifying Ascletis entry and exit points for their positions.

When running Ascletis Pharma's price analysis, check to measure Ascletis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascletis Pharma is operating at the current time. Most of Ascletis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascletis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascletis Pharma's price. Additionally, you may evaluate how the addition of Ascletis Pharma to your portfolios can decrease your overall portfolio volatility.